L. Rimsky

发表

Functional replacement of the HIV-1 rev protein by the HTLV-1 rex protein

M. Malim, B. Cullen, J. Hauber, 1988, Nature.

Virologic and Enzymatic Studies Revealing the Mechanism of K65R- and Q151M-Associated HIV-1 Drug Resistance Towards Emtricitabine and Lamivudine

B. Canard, K. Borroto-Esoda, Joy Y. Feng, 2006, Nucleosides, nucleotides & nucleic acids.

Cloning and expression of a cDNA for human thioredoxin.

F. Galibert, P. Wingfield, J. Jacquot, 1988, The Journal of biological chemistry.

Infection Woodchuck Model of Hepatitis B Virus Delivery of Gamma Interferon in the Emtricitabine with Adenovirus-Mediated Effect of a Combination of Clevudine and

M. Chevallier, F. Zoulim, S. Guerret, 2004 .

Effect of a Combination of Clevudine and Emtricitabine with Adenovirus-Mediated Delivery of Gamma Interferon in the Woodchuck Model of Hepatitis B Virus Infection

M. Chevallier, F. Zoulim, S. Guerret, 2004, Antimicrobial Agents and Chemotherapy.

RexTransregulation ofHumanT-Cell Leukemia Virus TypeIIGeneExpression

Jerome H. Kim, W. Greene, P. Kaufman, 1991 .

Stimulation oftheHumanImmunodeficiency VirusType1 Enhancer bytheHumanT-Cell Leukemia VirusTypeItaxGeneProduct Involves theAction ofInducible Cellular Proteins

B. Franza, W. Greene, J. Lowenthal, 1989 .

Efficacy and safety of TMC278 in antiretroviral-naive HIV-1 patients: week 96 results of a phase IIb randomized trial

K. Ruxrungtham, E. Katabira, D. Steyn, 2010, AIDS.

B-cell-derived interleukin-1.

T. Tursz, H. Wakasugi, J. Bertoglio, 1987, Annales de l'Institut Pasteur. Immunology.

Determinants of Human Immunodeficiency Virus Type 1 Resistance to gp41-Derived Inhibitory Peptides

T. Matthews, D. Shugars, L. Rimsky, 1998, Journal of Virology.

Epstein-Barr virus-containing B-cell line produces an interleukin 1 that it uses as a growth factor.

T. Tursz, H. Wakasugi, J. Bertoglio, 1987, Proceedings of the National Academy of Sciences of the United States of America.

Effects of Pyrimidine and Purine Analog Combinations in the Duck Hepatitis B Virus Infection Model

F. Zoulim, C. Trépo, C. Jamard, 2003, Antimicrobial Agents and Chemotherapy.

Preclinical and clinical development of the anti-HIV, anti-HBV oxathiolane nucleoside analog emtricitabine

R. Schinazi, D. Liotta, G. Painter, 2007, Frontiers in Viral Hepatitis.

Comparative analysis of the HTLV-I Rex and HIV-1 Rev trans-regulatory proteins and their RNA response elements.

W C Greene, S Y Le, J V Maizel, 1989, Genes & development.

Week 96 efficacy and safety of rilpivirine in treatment-naive, HIV-1 patients in two Phase III randomized trials

H. Stellbrink, A. Lazzarin, P. Williams, 2013, AIDS.

Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial

A. Lazzarin, M. Saag, P. Cahn, 2011, The Lancet.

Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial

B. Clotet, K. Ruxrungtham, M. Johnson, 2011, The Lancet.

Efficacy and Safety of Rilpivirine (TMC278) Versus Efavirenz at 48 Weeks in Treatment-Naive HIV-1–Infected Patients: Pooled Results From the Phase 3 Double-Blind Randomized ECHO and THRIVE Trials

B. Clotet, M. Johnson, M. Saag, 2012, Journal of acquired immune deficiency syndromes.

Long-term efficacy, safety, and tolerability of rilpivirine (RPV, TMC278) in HIV type 1-infected antiretroviral-naive patients: week 192 results from a phase IIb randomized trial.

K. Ruxrungtham, A. Pozniak, B. Grinsztejn, 2011, AIDS research and human retroviruses.

TMC278, a Next-Generation Nonnucleoside Reverse Transcriptase Inhibitor (NNRTI), Active against Wild-Type and NNRTI-Resistant HIV-1

Dirk Jochmans, Hilde Azijn, Gaston Picchio, 2009, Antimicrobial Agents and Chemotherapy.

Rilpivirine versus efavirenz with emtricitabine/tenofovir disoproxil fumarate in treatment-naïve HIV-1-infected patients with HIV-1 RNA ≤100,000 copies/mL: week 96 pooled ECHO/THRIVE subanalysis.

K. White, C. Orkin, C. Cohen, 2014, AIDS patient care and STDs.

96-Week Resistance Analyses of Rilpivirine in Treatment-Naive, HIV-1-Infected Adults from the Echo and Thrive Phase Iii Trials

V. van Eygen, J. Vingerhoets, G. Picchio, 2013, Antiviral therapy.

Rilpivirine vs. efavirenz in HIV-1 patients with baseline viral load 100 000 copies/ml or less: week 48 phase III analysis

N. Clumeck, J. Molina, L. Rimsky, 2013, AIDS.

Pre-Existing Mutations in the Rilpivirine Phase Iii Trials Echo and Thrive: Prevalence and Impact on Virological Response

V. van Eygen, J. Vingerhoets, G. Picchio, 2013, Antiviral therapy.

Genotypic and Phenotypic Characterization of HIV-1 Isolates Obtained From Patients on Rilpivirine Therapy Experiencing Virologic Failure in the Phase 3 ECHO and THRIVE Studies: 48-Week Analysis

B. Clotet, J. Eron, V. van Eygen, 2012, Journal of acquired immune deficiency syndromes.

The HIV-1 Reverse Transcriptase M184I Mutation Enhances the E138K-Associated Resistance to Rilpivirine and Decreases Viral Fitness

K. White, V. van Eygen, K. Babaoglu, 2012, Journal of acquired immune deficiency syndromes.

Trans-dominant inactivation of HTLV-I and HIV-1 gene expression by mutation of the HTLV-I Rex transactivator

W. Greene, E. Dixon, L. Rimsky, 1989, Nature.

Stimulation of the human immunodeficiency virus type 1 enhancer by the human T-cell leukemia virus type I tax gene product involves the action of inducible cellular proteins

B. Franza, M. Siekevitz, W. Greene, 1989, Journal of virology.

Vaccine-induced protection of chimpanzees against infection by a heterologous human immunodeficiency virus type 1

M. Kieny, P. Fultz, F. Barré-Sinoussi, 1995, Journal of virology.

Compilation and prevalence of mutations associated with resistance to non-nucleoside reverse transcriptase inhibitors

M. de Béthune, H. Azijn, J. Vingerhoets, 2009, Antiviral therapy.

Rex transregulation of human T-cell leukemia virus type II gene expression

W. Greene, P. Kaufman, S. Hanly, 1991, Journal of virology.

Purification to homogeneity and NH2-terminal amino acid sequence of a novel interleukin 1 species derived from a human B cell line.

P. Ferrara, T. Tursz, H. Wakasugi, 1986, Journal of immunology.

In vitro immune response to sheep erythrocytes in macrophage depleted cultures. Restoration with interleukine 1 or a monokine from resident macrophages and stimulation by N-acetyl-muramyl-L-alanyl-D-isoglutamine (MDP).

V. Souvannavong, A. Adam, L. Rimsky, 1983, Biochemical and biophysical research communications.

B-cell line-derived interleukin 1 is cytotoxic for melanoma cells and promotes the proliferation of an astrocytoma cell line.

J. Bertoglio, L. Lachman, L. Rimsky, 1987, Lymphokine research.

Flow cytometry resonance energy transfer suggests an association between low-affinity interleukin 2 binding sites and HLA class I molecules.

A. Harel-Bellan, W. Farrar, L. Rimsky, 1990, The Biochemical journal.

Prevalence in the Usa of Rilpivirine Resistance-Associated Mutations in Clinical Samples and Effects on Phenotypic Susceptibility to Rilpivirine and Etravirine

V. van Eygen, M. Haddad, J. Vingerhoets, 2014, Antiviral therapy.

Short communication: activity of etravirine on different HIV type 1 subtypes: in vitro susceptibility in treatment-naive patients and week 48 pooled DUET study data.

M. de Béthune, H. Azijn, J. Vingerhoets, 2010, AIDS research and human retroviruses.

Pooled Week 96 efficacy, resistance and safety results from the double-blind, randomised, Phase III trials comparing rilpivirine (RPV, TMC278) versus efavirenz (EFV) in treatment-naïve, HIV-1-infected adults

H. Stellbrink, A. Lazzarin, P. Williams, 2011 .

Deep sequencing analysis of HIV‐1 reverse transcriptase at baseline and time of failure in patients receiving rilpivirine in the phase III studies ECHO and THRIVE

J. Aerssens, V. van Eygen, J. Vingerhoets, 2016, Journal of medical virology.

Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial

A. Lazzarin, M. Saag, P. Cahn, 2011, The Lancet.